Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
May 27
Oceanography: Sea flow structures could aid search and rescue operationsNature Communications
-
May 27
Planetary science: Determining the trajectory of the Chicxulub impactNature Communications
-
May 26
Astronomy: Close encounters spawn stellar birthsNature Astronomy
-
May 21
Astronomy: Early disk galaxy puts formation models in a spinNature
-
May 19
Planetary science: How mud might flow on MarsNature Geoscience
-
May 19
Environment: Flooding impacts emergency response time in EnglandNature Sustainability
